clinical trial · NCT06393465
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
Pfizer·—·completed·n = 50
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)Tafamidis
brief summary
This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Transthyretin Amyloidosis using data that already exist in patients' medical records
started
Jun 15, 2024
primary completion
Mar 13, 2026
completion
Mar 13, 2026
last updated
Mar 24, 2026
official title
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol